Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
Low-dose naltrexone shows promise for long COVID
Low-dose naltrexone shows promise for long COVID

We are on our summer break and the editorial office is closed until 13 January. In the meantime, please enjoy our Summer Hiatus series, in which our journalists curate an eclectic mix from our news and clinical archives throughout the year, The Conversation and other publications we share content with. Please note the comment function has been turned off while we are away. Happy reading!
This article was first published online on 11 September 2024.
Psychiatrist David Codyre reviews the growing evidence for low-dose naltrexone in the treatment of functional syndromes such as fibromyalgia, chronic fatigue and long COVID
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
1. Toljan K, Vrooman B. Low-dose naltrexone (LDN) – review of therapeutic utilization. Med Sci (Basel) 2018;6(4):82.
2. Hatfield E, Phillips K, Swidan S, et al Use of low-dose naltrexone in the management of chronic pain conditions: A systematic review. J Am Dent Assoc 2020;151(12):891–902.e1.
3. Lie MRKL, van der Giessen J, Fuhler GM, et al. Low dose naltrexone for induction of remission in inflammatory bowel disease patients. J Transl Med 2018;16(1):55.
4. O’Kelly B, Vidal L, McHugh T, et al. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain Behav Immun Health 2022;24:100485.